# A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma

> **NCT05299424** · PHASE1,PHASE2 · RECRUITING · sponsor: **Keymed Biosciences Co.Ltd** · enrollment: 48 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** CM336_group 1
- **DRUG:** CM336_group 2a
- **DRUG:** CM336_group 2b
- **DRUG:** CM336_group 3a
- **DRUG:** CM336_group 3b
- **DRUG:** CM336_group 4a
- **DRUG:** CM336_group 4b
- **DRUG:** CM336_group 5
- **DRUG:** CM336_group 6a
- **DRUG:** CM336_group 6b
- **DRUG:** CM336_group 7
- **DRUG:** CM336_group 8a
- **DRUG:** CM336_group 8b
- **DRUG:** CM336_group 9
- **DRUG:** CM336_RP2D

## Key facts

- **NCT ID:** NCT05299424
- **Lead sponsor:** Keymed Biosciences Co.Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-08-09
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2024-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05299424

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05299424, "A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05299424. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*